MARKET

NEOS

NEOS

Neos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7180
-0.0320
-4.27%
Closed 16:00 04/01 EDT
OPEN
0.7700
PREV CLOSE
0.7500
HIGH
0.7799
LOW
0.7050
VOLUME
90.72K
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
0.6000
MARKET CAP
35.72M
P/E (TTM)
-2.1118
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NEOS stock price target is 7.00 with a high estimate of 10.00 and a low estimate of 2.000.

EPS

NEOS News

More
  • Neos Therapeutics Statement: COVID-19 Update
  • GlobeNewswire · 2d ago
  • Edited Transcript of NEOS earnings conference call or presentation 13-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 6d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Neos Therapeutics, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know
  • Simply Wall St. · 03/17 13:25

Industry

Pharmaceuticals
-2.46%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About NEOS

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
More

Webull offers kinds of Neos Therapeutics Inc stock information, including NASDAQ:NEOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEOS stock news, and many more online research tools to help you make informed decisions.